Hims & Hers shifts business model after Novo deal [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
But the story's changing. After the company's Novo Nordisk ( NVO ) deal and the end of the FDA shortage, Hims is shifting to a broader mix of branded, FDA-approved GLP-1s while pulling back from compounded supply. This is a shift in how the business operates. The question now is whether HIMS can build a profitable, durable model. In simple terms, Hims & Hers is an online health care platform that helps people get prescriptions and treatments without visiting a doctor's office. The company makes money by connecting patients with licensed providers and selling subscription-based treatments across weight loss, dermatology, mental health, and more. The business's competitive advantage comes from its brand, digital experience, and growing role as a distribution layer between patients and drugmakers, especially as it expands partnerships with companies like Novo Nordisk. The long-term opportunity is still meaningful if Hims can scale this model and maintain strong unit economic
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Vaxess Technologies raises $50m, rebrands to Terrestrial Bio [Yahoo! Finance]Yahoo! Finance
- Eli Lilly vs Novo Nordisk: Which Obesity Drug Stock Is the Better Buy? [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk: A Comeback Story In The World's Fastest-Growing Drug Market [Seeking Alpha]Seeking Alpha
- FDA Approval Of Awiqli Adds New Dimension To Novo Nordisk Story [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 3/27/26 - Form 6-K
- 3/27/26 - Form 6-K
- 3/26/26 - Form 6-K
- NVO's page on the SEC website